Introduction Clostridioides difficile infection(CDI)is a common gastrointestinal illness worldwide,with increased prevalence and worse outcomes in patients with inflammatory bowel disease(IBD)[1].Fecal microbiota tran...Introduction Clostridioides difficile infection(CDI)is a common gastrointestinal illness worldwide,with increased prevalence and worse outcomes in patients with inflammatory bowel disease(IBD)[1].Fecal microbiota transplant(FMT)is an effective treatment for recurrent CDIs(RCDIs)with minimal serious adverse events(SAEs)reported[2].While immunosuppressive medications increase susceptibility to infections,studies have shown that FMT does not increase SAE risk in immunocompromised patients(including IBD patients on immunosuppressive therapy)[3].展开更多
文摘Introduction Clostridioides difficile infection(CDI)is a common gastrointestinal illness worldwide,with increased prevalence and worse outcomes in patients with inflammatory bowel disease(IBD)[1].Fecal microbiota transplant(FMT)is an effective treatment for recurrent CDIs(RCDIs)with minimal serious adverse events(SAEs)reported[2].While immunosuppressive medications increase susceptibility to infections,studies have shown that FMT does not increase SAE risk in immunocompromised patients(including IBD patients on immunosuppressive therapy)[3].
